{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:13:22Z","timestamp":1789881202715,"version":"4.0.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of anlotinib combined with envafolimab in the treatment of unresectable or metastatic liposarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective study enrolled 15 patients with unresectable or metastatic liposarcoma, who were treated at the Retroperitoneal Tumor Surgery Research Center of Qingdao University Affiliated Hospital between April 2022 and November 2023. The treatment regimen consisted of anlotinib combined with envafolimab. Treatment efficacy was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1. Treatment-related adverse events (TRAEs) were assessed using Common Terminology Criteria for Adverse Events version 5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 15 patients with unresectable or metastatic liposarcoma were included; among them, seven were male (46.7%) and eight were female (53.3%), with a median age of 55 years. The pathological subtype distribution was as follows: three (20.0%) patients with well-differentiated liposarcoma, 11 (73.3%) patients with dedifferentiated liposarcoma, and one (6.7%) patient with myxoid liposarcoma. At 12 weeks post-diagnosis, none of the patients achieved a complete response. The objective response rate was 6.7%, with one patient (6.7%) achieving a partial response. Disease stability was observed in 10 (66.6%) patients, which corresponded to a disease control rate of 73.3%. Disease progression occurred in four (26.7%) patients. The median follow-up time was 16.9 months and the median progression-free survival time was 14.2 months. Seven patients experienced TRAEs, of whom three (42.2%) had grade 3\u20134 TRAEs. The most common TRAEs were liver function abnormalities, hypertension, and fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anlotinib combined with envafolimab demonstrates promising efficacy and manageable safety in treating unresectable or metastatic liposarcoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2024.1502945","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T01:18:20Z","timestamp":1736471900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study"],"prefix":"10.3389","volume":"14","author":[{"given":"Hongliang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qisheng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/his.2013.64.issue-1","article-title":"The evolving classification of soft tissue tumours\u2013an update based on the new 2013 WHO classification","volume":"64","author":"Fletcher","year":"2014","journal-title":"Histopathology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2729","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S112580","article-title":"Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas","author":"De Vita","year":"2016","journal-title":"OncoTargets Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2022.03.001","article-title":"WHO pathology: Highlights of the 2020 sarcoma update","volume":"31","author":"Schaefer","year":"2022","journal-title":"Surg Oncol Clinics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2016.05.007","article-title":"Liposarcoma: multimodality management and future targeted therapies","volume":"25","author":"Crago","year":"2016","journal-title":"Surg Oncol Clinics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.213","article-title":"Application of molecular biology to individualize therapy for patients with liposarcoma","volume":"35","author":"Abbas Manji","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13046-021-01963-1","article-title":"The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models","volume":"40","author":"De Vita","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40164-024-00540-4","article-title":"Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment","volume":"13","author":"Vanni","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B9","article-title":"Assessment of angiogenesis in soft-tissue tumors","volume":"46","author":"Baneth","year":"2005","journal-title":"Rom J Morphol Embryol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3983","article-title":"First-line anlotinib treatment for soft-tissue sarcoma in chemotherapy-ineligible patients: an open-label, single-arm, phase 2 clinical trial","volume":"30","author":"Li","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102240","article-title":"Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial","volume":"64","author":"Xu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001023","article-title":"Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated\/dedifferentiated liposarcoma: a single-center retrospective study","volume":"32","author":"Li","year":"2021","journal-title":"Anti-Cancer Drugs"},{"key":"B14","article-title":"Expert consensus on treatment of Retroperitoneal tumors in China(Edition 2019)","volume":"41","year":"2019","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775761","article-title":"Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and histotype tailored review","volume":"12","author":"Roulleaux Dugage","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts","author":"Burgess","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7027","article-title":"The role of immunotherapy in the management of soft tissue sarcomas: current landscape and future outlook","volume":"20","author":"Banks","year":"2022","journal-title":"J Natl Compr Cancer Network"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00891-5","article-title":"PD1\/PD-L1 targeting in advanced soft-tissue sarcomas: A pooled analysis of phase II trials","volume":"13","author":"Italiano","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-6041","article-title":"Turning \u2018Cold\u2019tumors \u2018Hot\u2019: immunotherapies in sarcoma","volume":"9","author":"Rytlewski","year":"2021","journal-title":"Ann Trans Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17588359241276968","DOI":"10.1177\/17588359241276968","article-title":"Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma","volume":"16","author":"Jia","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.21037\/atm-23-460","article-title":"Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study","volume":"11","author":"Wu","year":"2023","journal-title":"Ann Transl Med"},{"key":"B26","article-title":"Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma","volume":"102","author":"Guo","year":"2022","journal-title":"Zhonghua yi xue za zhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.11569","article-title":"Phase I\/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated","author":"Zhou","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.066","article-title":"Peristomal pemphigoid: A single-center retrospective cohort study","volume":"86","author":"Nowsheen","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13569-016-0064-0","article-title":"Response to anti-PD1 therapy with nivolumab in metastatic sarcomas","volume":"6","author":"Paoluzzi","year":"2016","journal-title":"Clin sarcoma Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J immunotherapy Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1502945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T01:18:24Z","timestamp":1736471904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1502945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":31,"alternative-id":["10.3389\/fonc.2024.1502945"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1502945","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"article-number":"1502945"}}